Explore the top publicly listed cannabis firms and market trends driving global valuation.
Brains Bioceutical Corp. has announced plans to list on Nasdaq, in what would be the first US public-market debut for a UK-based cannabinoid pharma manufacturer since GW Pharmaceuticals was acquired by Jazz in 2021.
Trulieve’s uplisting to the NYSE, the first of its kind in US history, has undoubtedly caught the attention of every large North American cannabis operator.
Cannabis stocks have, for the last five years or so, represented one of, if not the worst-performing, niche categories on any exchange.
For much of the past five years, the cannabis industry has been defined by disappointment.
Last week’s rescheduling announcement came as a surprise to many, not least to us here at Business of Cannabis.
The second quarter of 2026 has brought tentative signs of stabilisation to a cannabis sector that spent much of 2025 fighting for survival.
US Medicare patients have now been given access to cannabidiol (CBD) products through a landmark federal pilot scheme, helping boost cannabis stocks.
Bipartisan lawmakers have reintroduced a bill to the House of Representatives that would provide a pathway for cannabis businesses to list on the US stock exchange, accessing the institutional capital they sorely need.
Late last month, NASDAQ-listed cannabis operator Flora Growth, which once operated one of Colombia’s largest outdoor cultivation facilities, became the latest to exit the cannabis industry, rebranding as an AI-focused digital asset firm ZeroStack Corp.
